- Home
- QD vs LRMR Comparison
QD vs LRMR Comparison
Compare QD & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QD
- LRMR
- Stock Information
- Founded
- QD 2014
- LRMR N/A
- Country
- QD China
- LRMR United States
- Employees
- QD N/A
- LRMR N/A
- Industry
- QD Finance: Consumer Services
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- QD Finance
- LRMR Health Care
- Exchange
- QD Nasdaq
- LRMR Nasdaq
- Market Cap
- QD 433.7M
- LRMR 426.9M
- IPO Year
- QD 2017
- LRMR N/A
- Fundamental
- Price
- QD $2.99
- LRMR $3.19
- Analyst Decision
- QD
- LRMR Strong Buy
- Analyst Count
- QD 0
- LRMR 9
- Target Price
- QD N/A
- LRMR $19.44
- AVG Volume (30 Days)
- QD 391.8K
- LRMR 639.4K
- Earning Date
- QD 03-17-2025
- LRMR 03-13-2025
- Dividend Yield
- QD N/A
- LRMR N/A
- EPS Growth
- QD N/A
- LRMR N/A
- EPS
- QD 0.03
- LRMR N/A
- Revenue
- QD $32,502,011.00
- LRMR N/A
- Revenue This Year
- QD N/A
- LRMR N/A
- Revenue Next Year
- QD N/A
- LRMR N/A
- P/E Ratio
- QD $111.50
- LRMR N/A
- Revenue Growth
- QD 4.27
- LRMR N/A
- 52 Week Low
- QD $1.52
- LRMR $3.01
- 52 Week High
- QD $3.34
- LRMR $12.91
- Technical
- Relative Strength Index (RSI)
- QD 51.41
- LRMR 37.56
- Support Level
- QD $2.99
- LRMR $3.06
- Resistance Level
- QD $3.34
- LRMR $3.52
- Average True Range (ATR)
- QD 0.16
- LRMR 0.22
- MACD
- QD 0.01
- LRMR 0.02
- Stochastic Oscillator
- QD 43.65
- LRMR 15.66
About QD Qudian Inc. each representing one
Qudian Inc is a consumer-oriented technology company engaged in the operation of online platforms to provide small consumer credit products in the People's Republic of China. It aims to empower financial institutions with its technological capabilities, help them improve marketing and operating efficiency, and enable financial institutions to efficiently connect their diversified financial products with scene traffic across the entire network It derives a majority of its revenue from the People's Republic of China.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.